2. Vías de señalización
  3. Epigenetics
  4. DNA Methyltransferase
  5. DNMT1 Isoform

DNMT1

DNMT1 (DNA methyltransferase 1) is the principal maintenance DNA methyltransferase that preferentially recognizes hemimethylated CpG sites and preserves DNA methylation patterns during DNA replication, thereby supporting epigenetic inheritance and stable gene regulation[1][2]. Mechanistically, DNMT1 functions within the DNA methylation machinery that maintains chromatin states, transcriptional programs, and genome stability, and its recruitment to newly replicated DNA is coordinated by factors such as UHRF1[3][4]. Through maintenance of CpG methylation, DNMT1 contributes to developmental processes, cellular identity, and long-term repression of transposable elements[1][5]. In disease contexts, aberrant DNMT1 activity is strongly associated with cancer, where sustained DNA methylation can promote silencing of tumor-suppressor genes and support malignant phenotypes[1][6][7]. Experimental studies further demonstrate that selective depletion of DNMT1 induces global and gene-specific demethylation and reactivates silenced tumor-suppressor genes in human cancer cells, highlighting its central role in epigenetic regulation[7]. Compared with the related de novo methyltransferases DNMT3A and DNMT3B, which establish new methylation patterns, DNMT1 primarily propagates existing methylation marks after DNA replication, although recent evidence indicates that DNMT1 can also exhibit context-dependent de novo methylation activity, particularly at retrotransposon loci[5][8]. For experimental applications, DNMT1 remains a major epigenetic drug target, and both nucleoside-based and emerging selective non-nucleoside inhibitors are widely used to investigate DNA methylation dynamics and therapeutic reprogramming of aberrant epigenetic states[6][9].

DNMT1 Produits associés (31):

Cat. No. Nom du produit Effet Pureté
  • HY-A0004
    Decitabine
    		Inhibitor 99.97%
    Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity.
  • HY-10586
    5-Azacytidine
    		Inhibitor 99.91%
    5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes. 5-Azacytidine induces cell autophagy.
  • HY-135146
    GSK-3484862
    		Inhibitor 99.95%
    GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1). GSK-3484862 induces DNA hypomethylation to against cancer. GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicity.
  • HY-112288
    C188-9
    		Inhibitor 99.84%
    C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia.
  • HY-13642
    RG108
    		Inhibitor 99.93%
    RG108 (N-Phthalyl-L-tryptophan) is a non-nucleoside DNA methyltransferases (DNMTs) inhibitor (IC50=115 nM) that blocks the DNMTs active site. RG108 (N-Phthalyl-L-tryptophan) causes demethylation and reactivation of tumor suppressor genes, but it does not affect the methylation of centromeric satellite sequences.
  • HY-179409
    MC3817
    		Inhibitor
    MC3817 is a selective DNMT1 inhibitor. MC3817 inhibits DNMT1 and DNMT3A/3L with IC50s of 0.044 μM and > 10μM, respectively. MC3817 inhibits P53-dependent cancer cell proliferation, induces apoptosis and DNA damage MC3817 elevates cleaved Caspase 3, P53, and γH2AX. MC3817 can be used in non-small cell lung cancer, colon cancer, cervical cancer, triple-negative breast cancer and histiocytic lymphoma research.
  • HY-179409A
    MC3817 free base
    		Inhibitor
    MC3817 free base is a selective DNMT1 inhibitor. MC3817 free base inhibits DNMT1 and DNMT3A/3L with IC50s of 0.044 μM and > 10μM, respectively. MC3817 free base inhibits P53-dependent cancer cell proliferation, induces apoptosis and DNA damage. MC3817 free base elevates cleaved Caspase 3, P53, and γH2AX. MC3817 free base can be used in non-small cell lung cancer, colon cancer, cervical cancer, triple-negative breast cancer and histiocytic lymphoma research.
  • HY-182009
    DNMT-IN-6
    		Inhibitor
    DNMT-IN-6 is a DNA methyltransferase inhibitor with activity against DNMT1, DNMT3A, and DNMT3B. DNMT-IN-6 drives demethylation, and restores TMS1 tumor suppressor gene expression. DNMT-IN-6 induces apoptosis, causes G2/M phase arrest, disrupts mitochondrial integrity, and activates the intrinsic caspase cascade (3/7/9). DNMT-IN-6 inhibits tumor growth, and improves survival in xenograft models. DNMT-IN-6 can be used for the research of cancer, such as diffuse large B-cell lymphoma.
  • HY-13962
    SGI-1027
    		Inhibitor 99.79%
    SGI-1027 is a DNA methyltransferase (DNMT) inhibitor, with IC50s of 7.5 μM, 8 μM, and 12.5 μM for DNMT3B, DNMT3A, and DNMT1 with poly(dI-dC) as substrate.
  • HY-13420
    Zebularine
    		Inhibitor 99.49%
    Zebularine (NSC309132; 4-Deoxyuridine) is a DNA methyltransferase inhibitor. Zebularine also inhibits cytidine deaminase with a Ki of 0.95 μM.
  • HY-B2230
    Hinokitiol
    		Inhibitor 99.83%
    Hinokitiol is a component of essential oils isolated from Chymacyparis obtusa, reduces Nrf2 expression, and decreases DNMT1 and UHRF1 mRNA and protein expression, with anti-infective, anti-oxidative, and anti-tumor activities.
  • HY-101925
    CM-272
    		Inhibitor 98.70%
    CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a, DNMT1, DNMT3A, DNMT3B and GLP with IC50s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing IFN-stimulated genes and immunogenic cell death.
  • HY-15229
    Guadecitabine sodium
    		Inhibitor 99.97%
    Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
  • HY-B2194
    γ-Oryzanol
    		Inhibitor 99.66%
    γ-Oryzanol is a potent DNA methyltransferases (DNMTs) inhibitor in the striatum of mice. γ-Oryzanol significantly inhibits the activities of DNMT1 (IC50=3.2 μM), DNMT3a (IC50=22.3 μM).
  • HY-12746
    DC-05
    		Inhibitor 99.04%
    DC-05 is a DNA methyltransferase 1 (DNMT1) inhibitor, with an IC50 and a Kd of 10.3 μM and 1.09 μM, respectively.
  • HY-139015
    5-Aza-4'-thio-2'-deoxycytidine
    		Inhibitor 99.89%
    5-Aza-4'-thio-2'-deoxycytidine (5-Aza-T-dCyd) is an orally active DNA methyltransferase I (DNMT1) inhibitor. 5-Aza-4'-thio-2'-deoxycytidine, a sulfur-containing deoxy-cytidine analog, has the potential for DNA hypomethylating and has antitumor effects.
  • HY-117421A
    CM-579 trihydrochloride
    		Inhibitor
    CM-579 trihydrochloride is a first-in-class reversible, dual inhibitor of G9a and DNMT, with IC50 values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells.
  • HY-12747
    DC_517
    		Inhibitor 99.33%
    DC_517 is a DNA methyltransferase 1 (DNMT1) inhibitor, with an IC50 and a Kd of 1.7 μM and 0.91 μM, respectively.
  • HY-139664A
    (R)-GSK-3685032
    		Inhibitor 98.97%
    (R)-GSK-3685032 is the R-enantiomer of GSK-3685032. GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition.
  • HY-173002
    MS9024
    		Degrader 99.83%
    MS9024 is the degrader for DNA methyltransferase 1 that degrades DNMT1 in cell HCT116 through the ubiquitin-proteasome pathway with a DC50 of 35 nM (DC50 in MDA-MB-468 and H1299 is 254 nM and 101 nM). MS9024 also inhibits DNMT1 with an IC50 of 0.43 μM.
Cat. No. Nom du produit / Synonyms Application Reactivity